NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TAE Life Sciences

TAE Life Sciences

Private
Irvine, CaliforniaHealthcare & Life Scienceshttps://taelifesciences.com/

Last Round

Series C

Jun 3, 2024

Est. Valuation

$400M

Total Funding Raised

$40M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

TAE Life Sciences is a biotechnology company that develops biologically targeted radiation therapies utilizing Boron Neutron Capture Therapy (BNCT) to treat invasive and challenging cancers.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

boron neutron capture therapyBNCTaccelerator-based radiation therapytargeted cancer therapyboron-10 drugsneutron beam systemprecision oncologymedical particle acceleratorcancer treatment technologyradiation oncologycellular-level therapynext-gen radiationradiotherapy hardwaremedical device consumables

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TAE Life Sciences Comparables

Compare TAE Life Sciences with similar companies based on industry and business-model similarity.

TAE Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Dawon Medax
85%
Neutron Therapeutics
84%
Neuboron Medical Group
83%

TAE Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 3, 2024
Series BJun 2, 2020
Series AMar 12, 2018

Key People

Founding team and executive leadership

Robert Hill

Chief Executive Officer

Executive Team

TAE Life Sciences Investors

Notable investors and investment history

TAE Life Sciences investors
InvestorRounds
Rising Tide FundSeries B, Series A
ARTIS VenturesSeries B, Series A
Big Sky PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 37% MoM.

  • Apr 1, 2026

    CNAO identified as a key deployment site.

TAE Life Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TAE Life Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TAE Life Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersIrvine, California
Employee Range75
Year Founded2017
Last FundingJun 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.